Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

46.77 +1.88 (+4.19%)

Delayed Quote Updated: 1:18 PM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

What Alkermes (ALKS) Said on Its Q3 Earnings Call ↗

Today 13:14 EST

Alkermes (NASDAQ:ALKS) reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development...

Via MarketBeat

Topics Earnings

Alkermes plc Reports Third Quarter 2026 Financial Results

Today 7:05 EST

From Alkermes plc

Via Business Wire

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

October 30, 2026

From Alkermes plc

Via Business Wire

Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance ↗

July 28, 2026

Via Chartmill

Topics Earnings

Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗

May 05, 2026

Via Chartmill

Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗

April 29, 2026

Via Chartmill

Alkermes to Report Third Quarter Financial Results on November 3, 2026

October 20, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

October 13, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

September 21, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

September 16, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

September 10, 2026

From Alkermes plc

Via Business Wire

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 ↗

August 29, 2026

The insider still has significant holdings in the company, signaling confidence.

Via The Motley Fool

Topics Regulatory Compliance

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

August 24, 2026

From Alkermes plc

Via Business Wire

Alkermes Q2 Earnings Call Highlights ↗

July 28, 2026

Alkermes (NASDAQ:ALKS) reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following...

Via MarketBeat

Topics Earnings

Alkermes plc Reports Second Quarter 2026 Financial Results

July 28, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Second Quarter Financial Results on July 28, 2026

July 14, 2026

From Alkermes plc

Via Business Wire

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

July 13, 2026

From Alkermes plc

Via Business Wire

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

June 17, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

June 15, 2026

From Alkermes plc

Via Business Wire

Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗

June 10, 2026

Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for...

Via MarketBeat

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

June 04, 2026

From Alkermes plc

Via Business Wire

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 03, 2026

From Alkermes plc

Via Business Wire

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

May 26, 2026

From Alkermes plc

Via Business Wire

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

May 21, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

May 12, 2026

From Alkermes plc

Via Business Wire

Alkermes (ALKS) Q1 2026 Earnings Transcript ↗

May 05, 2026

Alkermes (ALKS) Q1 2026 Earnings Transcript

Via The Motley Fool

Alkermes plc Reports First Quarter 2026 Financial Results

May 05, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report First Quarter Financial Results on May 5, 2026

April 21, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

April 16, 2026

From Alkermes plc

Via Business Wire

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

April 14, 2026

From Alkermes plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.